Kun Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kun Zhao has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Yong Liu
Center for Artificial Intelligence in Medical Imaging, School of Artificial Intelligence, Beijing University of Posts and Telecommunications, Beijing, China
22 shared publications Pan Wang
Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China
12 shared publicationsBo Zhou
Department of Neurology, The Second Medical Centre, National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
11 shared publicationsHongxiang Yao
Department of Radiology, The Second Medical Centre, National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
11 shared publicationsXi Zhang
Department of Neurology, The Second Medical Centre, National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
10 shared publicationsYanhui Ding
School of Information Science and Engineering Shandong Normal University Jinan China
9 shared publications
Latest Publications
- 25 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (39)
Beyond statistical thresholds: Mapping sequential ATN cascade transitions via brain structural topography in Alzheimer’s disease
Alzheimer’s disease is widely conceptualized as a biological continuum initiated by amyloid-β (Aβ) accumulation, followed by tau aggregation and neurodegeneration. Although the ATN framework is commonly used to define disease stages, its static biomarker categories may not fully capture the dynamic pathological transitions that determine the optimal window for anti-Aβ therapies. Here, we introduce a Biological Continuum framework that distinguishes dynamic pathological cascades from static biomarker categories. Using neuroimaging-derived brain network topology, we identify four reproducible subgroups that exhibit distinct biological processes, biomarker signatures, and longitudinal cognitive trajectories. Integrated proteomic analyses suggest that these subgroups reflect sequential molecular transitions corresponding to early vulnerability, initiation, amplification, and terminal stages. Post hoc analysis indicates that slower cognitive decline after amyloid-targeting treatment was observed mainly in the initiation stage group. These findings provide a biologically grounded stratification system that captures disease dynamics overlooked by threshold-based models and offers mechanistic insight into the timing of anti-Aβ therapies.
- 25 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (39)
Beyond statistical thresholds: Mapping sequential ATN cascade transitions via brain structural topography in Alzheimer’s disease
Alzheimer’s disease is widely conceptualized as a biological continuum initiated by amyloid-β (Aβ) accumulation, followed by tau aggregation and neurodegeneration. Although the ATN framework is commonly used to define disease stages, its static biomarker categories may not fully capture the dynamic pathological transitions that determine the optimal window for anti-Aβ therapies. Here, we introduce a Biological Continuum framework that distinguishes dynamic pathological cascades from static biomarker categories. Using neuroimaging-derived brain network topology, we identify four reproducible subgroups that exhibit distinct biological processes, biomarker signatures, and longitudinal cognitive trajectories. Integrated proteomic analyses suggest that these subgroups reflect sequential molecular transitions corresponding to early vulnerability, initiation, amplification, and terminal stages. Post hoc analysis indicates that slower cognitive decline after amyloid-targeting treatment was observed mainly in the initiation stage group. These findings provide a biologically grounded stratification system that captures disease dynamics overlooked by threshold-based models and offers mechanistic insight into the timing of anti-Aβ therapies.
- Open Access
- 29 August 2026
- Published by Elsevier in SSRN Electronic Journal
Charting Sex Divergence in the Human Brain Across the Lifespan
Biological sex fundamentally shapes human brain organization, but sex-specific normative neuroanatomical trajectories across the lifespan remain largely uncharted. Here, we constructed independent, sex-specific lifespan brain charts using structural neuroimaging data from 59,915 healthy individuals (29,760 males and 30,155 females) ranging in age from 266 postconception days to 100 years. By examining 296 structural phenotypes across global, cortical, and subcortical measures, these models revealed widespread sex differences in maturational timing, with males reaching peak milestones later than females. These trajectories demonstrate that sex differences evolve dynamically, with phenotype-specific windows of emergence and maximal separation. Compared with conventional sex-pooled references, sex-specific models achieved superior predictive accuracy and reduced misestimation of individual deviations in healthy populations. Across five neuropsychiatric conditions, sex-specific models improved the detection of extreme deviations and revealed both shared and sex-dependent patterns of disorder-related neuroanatomical abnormalities. These sex-specific charts establish tailored normative references for assessing brain development, ageing, and disease.
- 29 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCharting Sex Divergence in the Human Brain Across the Lifespan
Biological sex fundamentally shapes human brain organization, but sex-specific normative neuroanatomical trajectories across the lifespan remain largely uncharted. Here, we constructed independent, sex-specific lifespan brain charts using structural neuroimaging data from 59,915 healthy individuals (29,760 males and 30,155 females) ranging in age from 266 postconception days to 100 years. By examining 296 structural phenotypes across global, cortical, and subcortical measures, these models revealed widespread sex differences in maturational timing, with males reaching peak milestones later than females. These trajectories demonstrate that sex differences evolve dynamically, with phenotype-specific windows of emergence and maximal separation. Compared with conventional sex-pooled references, sex-specific models achieved superior predictive accuracy and reduced misestimation of individual deviations in healthy populations. Across five neuropsychiatric conditions, sex-specific models improved the detection of extreme deviations and revealed both shared and sex-dependent patterns of disorder-related neuroanatomical abnormalities. These sex-specific charts establish tailored normative references for assessing brain development, ageing, and disease.
- Open Access
- 30 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (7) , e71638
Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease
INTRODUCTION: Mild cognitive impairment (MCI), a prodromal stage of Alzheimer's disease (AD), shows pronounced clinical heterogeneity poorly explained by pathology burden, representing a gap complicating prognosis. As the brain operates as a complex network for information integration, we hypothesized that connectome architecture mediates the link between AD pathology and clinical expression. METHODS: We developed a framework integrating structural and functional connectomes from multi‐center cohorts, performing connectome‐based subtyping in MCI, with analyses of upstream pathology, downstream phenotypes, and transcriptomic associations. RESULTS: This approach identified an “MCI‐compromised” (MCI‐C) subgroup characterized by extensive structural‐functional connectomic disruption and an “MCI‐preserved” (MCI‐P) subgroup with relatively preserved connectome integrity. Despite comparable pathology, MCI‐C demonstrated more severe neurodegeneration, accelerated cognitive decline, and elevated progression risk. Multiscale analyses linked these patterns to transcriptomic profiles of mitochondrial, synaptic, and neuroimmune processes. DISCUSSION: These findings demonstrate that the connectome acts as a critical mediator, rather than a passive endophenotype, shaping AD clinical expression.
- 30 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (7) , e71638
Open AccessHuman brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease
INTRODUCTION: Mild cognitive impairment (MCI), a prodromal stage of Alzheimer's disease (AD), shows pronounced clinical heterogeneity poorly explained by pathology burden, representing a gap complicating prognosis. As the brain operates as a complex network for information integration, we hypothesized that connectome architecture mediates the link between AD pathology and clinical expression. METHODS: We developed a framework integrating structural and functional connectomes from multi‐center cohorts, performing connectome‐based subtyping in MCI, with analyses of upstream pathology, downstream phenotypes, and transcriptomic associations. RESULTS: This approach identified an “MCI‐compromised” (MCI‐C) subgroup characterized by extensive structural‐functional connectomic disruption and an “MCI‐preserved” (MCI‐P) subgroup with relatively preserved connectome integrity. Despite comparable pathology, MCI‐C demonstrated more severe neurodegeneration, accelerated cognitive decline, and elevated progression risk. Multiscale analyses linked these patterns to transcriptomic profiles of mitochondrial, synaptic, and neuroimmune processes. DISCUSSION: These findings demonstrate that the connectome acts as a critical mediator, rather than a passive endophenotype, shaping AD clinical expression.
- Open Access
- 9 June 2026
- Published by Springer Nature in npj Digital Medicine
Forecasting Alzheimer’s disease progression via identity-preserved denoising diffusion generative adversarial network
Forecasting the progression of Alzheimer’s disease (AD) is essential for evaluating secondary prevention measures thought to modify the disease trajectory. However, accurate prediction of longitudinal MRIs remains challenging, particularly in preserving subject identity, as deep generative models may potentially generate plausible future MRIs of different individuals from a single baseline scan. In the present study, we developed a novel identity-preserved denoising diffusion generative adversarial network (IP-DDGAN) capable of rapidly generating subject-specific longitudinal MRIs conditioned on metadata. Concretely, we developed an identity-preservation strategy incorporating a metadata-guided module and identity-preserved regularization terms to maintain subject identity in synthetic longitudinal MRIs. Furthermore, we comprehensively integrated morphometric, subject-identity-consistency, and image-level quality metrics to evaluate the fidelity and biological plausibility of synthetic longitudinal MRIs. The results demonstrate that the synthetic MRIs generated by IP-DDGAN retain biological and disease-related phenotypes and exhibit sufficient realism to support downstream applications. Our proposed model effectively captures temporal biological and disease-related changes and predicts distinct disease progression trajectories, including the clinically important transitions from cognitively normal (CN) to mild cognitive impairment (MCI) and from MCI to AD.
- 9 June 2026
- Published by Springer Nature in npj Digital Medicine
Open AccessForecasting Alzheimer’s disease progression via identity-preserved denoising diffusion generative adversarial network
Forecasting the progression of Alzheimer’s disease (AD) is essential for evaluating secondary prevention measures thought to modify the disease trajectory. However, accurate prediction of longitudinal MRIs remains challenging, particularly in preserving subject identity, as deep generative models may potentially generate plausible future MRIs of different individuals from a single baseline scan. In the present study, we developed a novel identity-preserved denoising diffusion generative adversarial network (IP-DDGAN) capable of rapidly generating subject-specific longitudinal MRIs conditioned on metadata. Concretely, we developed an identity-preservation strategy incorporating a metadata-guided module and identity-preserved regularization terms to maintain subject identity in synthetic longitudinal MRIs. Furthermore, we comprehensively integrated morphometric, subject-identity-consistency, and image-level quality metrics to evaluate the fidelity and biological plausibility of synthetic longitudinal MRIs. The results demonstrate that the synthetic MRIs generated by IP-DDGAN retain biological and disease-related phenotypes and exhibit sufficient realism to support downstream applications. Our proposed model effectively captures temporal biological and disease-related changes and predicts distinct disease progression trajectories, including the clinically important transitions from cognitively normal (CN) to mild cognitive impairment (MCI) and from MCI to AD.
- 1 April 2026
- Published by Springer Nature
- p. 570-584
An End-to-End Deep Learning Framework for Alzheimer's Disease Diagnosis by Using Multi-site and Multi-modal MRI Data
- 1 April 2026
- Published by Springer Nature
- p. 570-584
An End-to-End Deep Learning Framework for Alzheimer's Disease Diagnosis by Using Multi-site and Multi-modal MRI Data
- Open Access
- 5 February 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
A neuroimaging biomarker for disease staging in clinically diagnosed Alzheimer’s disease
Precision medicine for Alzheimer’s disease (AD) requires the development of a robust management framework grounded in individualized disease staging
- 5 February 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Open AccessA neuroimaging biomarker for disease staging in clinically diagnosed Alzheimer’s disease
Precision medicine for Alzheimer’s disease (AD) requires the development of a robust management framework grounded in individualized disease staging
- Open Access
- 28 November 2025
- Published by Springer Nature in Research Square
Forecasting Alzheimer’s Disease Progression via Identity-preserved Denoising Diffusion Generative Adversarial Network
Forecasting the progression of Alzheimer’s disease (AD) is essential for evaluating secondary prevention measures thought to modify the disease trajectory. However, accurate prediction of longitudinal MRIs remains challenging, particularly in preserving subject identity, as deep generative models may potentially generate plausible future MRIs of different individuals from a single baseline scan. In the present study, we developed a novel identity-preserved denoising diffusion generative adversarial network (IP-DDGAN) capable of rapidly generating subject-specific longitudinal MRIs conditioned on metadata. Concretely, we developed an identity-preservation strategy with a metadata-guided module and identity-preserved regularization terms to maintain subject identity in synthetic longitudinal MRIs. Furthermore, we comprehensively integrated the morphometrics, subject identity consistency and image-level quality metrics to evaluate the fidelity and biological plausibility of synthetic longitudinal MRIs. The results demonstrate that the synthetic MRIs generated by IP-DDGAN retain biological and disease-related phenotypes, exhibiting sufficient realism to support their application in downstream tasks. Our proposed model is capable of capturing temporal biological and disease-related changes and forecasting the different progression trajectories, including critical transitions from cognitively normal (CN) to mild cognitive impairment (MCI) and from MCI to AD.
- 28 November 2025
- Published by Springer Nature in Research Square
Open AccessForecasting Alzheimer’s Disease Progression via Identity-preserved Denoising Diffusion Generative Adversarial Network
Forecasting the progression of Alzheimer’s disease (AD) is essential for evaluating secondary prevention measures thought to modify the disease trajectory. However, accurate prediction of longitudinal MRIs remains challenging, particularly in preserving subject identity, as deep generative models may potentially generate plausible future MRIs of different individuals from a single baseline scan. In the present study, we developed a novel identity-preserved denoising diffusion generative adversarial network (IP-DDGAN) capable of rapidly generating subject-specific longitudinal MRIs conditioned on metadata. Concretely, we developed an identity-preservation strategy with a metadata-guided module and identity-preserved regularization terms to maintain subject identity in synthetic longitudinal MRIs. Furthermore, we comprehensively integrated the morphometrics, subject identity consistency and image-level quality metrics to evaluate the fidelity and biological plausibility of synthetic longitudinal MRIs. The results demonstrate that the synthetic MRIs generated by IP-DDGAN retain biological and disease-related phenotypes, exhibiting sufficient realism to support their application in downstream tasks. Our proposed model is capable of capturing temporal biological and disease-related changes and forecasting the different progression trajectories, including critical transitions from cognitively normal (CN) to mild cognitive impairment (MCI) and from MCI to AD.
- Open Access
- 26 November 2025
- Published by Springer Nature in Research Square
Functional Hierarchy Disruption: A Mechanistic Link to Cognitive Decline and Treatment Targets in Alzheimer’s Disease
Alzheimer’s disease (AD) is marked by disrupted brain network connectivity, which impairs functional hierarchy and contributes to cognitive decline. Two fundamental questions, however, remain open: what specific changes occur in the hierarchical organization of the AD brain, and whether rectifying these changes can restore cognitive function. To answer these, we first analyzed individualized functional hierarchical architecture across three large, independent fMRI datasets (MCADI, N = 711; ADNI, N = 621; OASIS-3, N = 506). We identified a reproducible pattern of hierarchical remodeling in AD, characterized by expansion of the dorsal attention network A and shrinkage of the control network A, with spatial variability shaped by underlying brain tissue properties. To evaluate the therapeutic relevance of this signature, we conducted a randomized controlled trial of transcranial alternating current stimulation (tACS; N=44). Targeted stimulation selectively reversed the remodeling trajectory, suppressing dorsal attention network expansion and countering control network contraction. These network improvements persisted for three months and were accompanied by sustained cognitive gains, with 80% of participants showing measurable improvement. Our results reveal a functional hierarchical signature of AD and establish its potential as a novel interventional target, while also providing mechanistic insights into the action of non-invasive neuromodulation.
- 26 November 2025
- Published by Springer Nature in Research Square
Open AccessFunctional Hierarchy Disruption: A Mechanistic Link to Cognitive Decline and Treatment Targets in Alzheimer’s Disease
Alzheimer’s disease (AD) is marked by disrupted brain network connectivity, which impairs functional hierarchy and contributes to cognitive decline. Two fundamental questions, however, remain open: what specific changes occur in the hierarchical organization of the AD brain, and whether rectifying these changes can restore cognitive function. To answer these, we first analyzed individualized functional hierarchical architecture across three large, independent fMRI datasets (MCADI, N = 711; ADNI, N = 621; OASIS-3, N = 506). We identified a reproducible pattern of hierarchical remodeling in AD, characterized by expansion of the dorsal attention network A and shrinkage of the control network A, with spatial variability shaped by underlying brain tissue properties. To evaluate the therapeutic relevance of this signature, we conducted a randomized controlled trial of transcranial alternating current stimulation (tACS; N=44). Targeted stimulation selectively reversed the remodeling trajectory, suppressing dorsal attention network expansion and countering control network contraction. These network improvements persisted for three months and were accompanied by sustained cognitive gains, with 80% of participants showing measurable improvement. Our results reveal a functional hierarchical signature of AD and establish its potential as a novel interventional target, while also providing mechanistic insights into the action of non-invasive neuromodulation.
- 1 November 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 7 (6) , e240508
Structural MRI–based Computer-aided Diagnosis Models for Alzheimer Disease: Insights into Misclassifications and Diagnostic Limitations
The 3D Nested Hierarchical Transformer model helped to accurately diagnose Alzheimer disease based on structural brain MRI scans. False-negative classifications were consistent across all computer-aided detection models, occurring primarily in patients with atypical Alzheimer disease and preserved cognition.
- 1 November 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 7 (6) , e240508
Structural MRI–based Computer-aided Diagnosis Models for Alzheimer Disease: Insights into Misclassifications and Diagnostic Limitations
The 3D Nested Hierarchical Transformer model helped to accurately diagnose Alzheimer disease based on structural brain MRI scans. False-negative classifications were consistent across all computer-aided detection models, occurring primarily in patients with atypical Alzheimer disease and preserved cognition.
- 20 September 2025
- Published by Springer Nature
- p. 142-152
DGM: Disentangled Generative Model for Detecting AD Individualized Pathological Changes via Pseudo-Healthy Synthesis
- 20 September 2025
- Published by Springer Nature
- p. 142-152
DGM: Disentangled Generative Model for Detecting AD Individualized Pathological Changes via Pseudo-Healthy Synthesis